• Acharya Shrikrishna and Bhat Archana.
• KS Hegde Medical Academy, Endocrinology.
• Afr Health Sci. 2023 Mar 1; 23 (1): 270275270-275.

IntroductionGenitourinary infections are common in Diabetes patients compared to the general population more so in patients with Sodium glucose co transporter 2 inhibitors (SGLT2i) treatment , So, we did a study to find the prevalence of genitourinary infection in T2DM patients treated with SGLT2i.MethodsOne hundred and twenty patients receiving SGLT2i, who had signs and symptoms indicative of genitourinary infections were enrolled into the study.ResultsThe mean age of presentation was 54.4 ± 7.7 years and percentage of males were 62 (51.66%). In this cohort, 72(60%) were treated with empagliflozin, 34(28.33%) with dapagliflozin and 14(11.66%) with canagliflozin. Twenty patients had genital mycotic infection and 4 had urinary tract infection. Female patients had higher incidence of infections than male patients with no statistically significant difference (P = ns). We did not find any significant correlation between age of the patient, gender, duration of disease and treatment, HbA1c, different types and dose of SGLT2i used with the incidence of genital mycotic infections (P = ns).ConclusionWe need to counsel the patients before starting SGLT2i regarding possible chance of getting genitourinary infection, proper genital hygiene, drinking plenty of water and consulting the doctor if any symptoms at the earliest.© 2023 Shrikrishna A et al.

19 keywords...

hide…